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Brain natriuretic peptide (BNP) and endothelin-1 (ET-1) both
exhibit natriuretic activity within the human kidney.
Furthermore, they both act partly through activation of the
endothelial nitric oxide pathway. Since ET-1 may cause
vasodilation and natriuresis via stimulation of the ET-B
receptor, the aim of the present study was to investigate
whether renal ET-B receptors participate in the renal actions
of BNP. In this placebo-controlled, crossover study, we
infused BNP (4 pmol/kg/min) or placebo (i.v.) for 1 h, with or
without co-infusion of the ET-B receptor antagonist BQ-788
(50 nmol/min) for 15 min on 4 separate days, in 10 healthy
subjects (mean age 5476 years.). During infusion, we
measured effective renal plasma flow (ERPF), and glomerular
filtration rate (GFR) using PAH/inulin clearance. Cardiac
output was measured before and after infusion, using
echocardiography. Blood pressure and heart rate (HR) were
monitored as well. Urine and plasma samples were taken
every hour to measure diuresis, natriuresis, cyclic 30,50
guanosine monophosphate, and ET-1 levels. BNP with or
without ET-B receptor blockade increased natriuresis and
diuresis. In addition, BNP alone increased GFR and filtered
load, without changing ERPF. BQ-788 infusion did not affect
renal hemodynamics or natriuresis. Neither BNP nor BQ-788
altered cardiac output, blood pressure, and heart rate. In
conclusion, the present study shows that selective ET-B
receptor blockade has no effect on the BNP-induced
natriuresis and glomerular filtration rate.
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Brain natriuretic peptide (BNP) stimulates natriuresis and
diuresis, but the renal mechanisms that are involved remain
unclear. Increases in glomerular filtration rate (GFR) and
renal plasma flow (RPF) could represent the intrarenal forces
that explain the enhanced natriuresis occurring during
systemic BNP infusion. However, La Villa et al.1 found a
natriuretic effect of BNP in the absence of changes in GFR
and RPF in healthy subjects. Furthermore, we observed in
hypertensive patients that intrarenal BNP infusion does not
induce significant changes in renal blood flow or creatinine
extraction (as a marker of glomerular filtration).2 This
suggests that BNP primarily acts at the tubular level in the
kidney. On the other hand, it may be that BNP, except for
inducing renal vasodilation, simultaneously stimulates a
vasoconstrictor mechanism with the net effect that RPF
remains constant. Indeed, it has demonstrated before that a
close relationship exists between BNP and intrarenal
endothelin-1 (ET-1) production.3 Apart from being a potent
vasoconstrictor, ET-1 exhibits intrarenal natriuretic activity
independently of changes in filtered load.4 The role of ET-1
in the kidney may even be dissociated from circulating ET-1.
In fact, De Feo et al. demonstrated that systemic infusion of
BNP is accompanied by increased urinary excretion of ET-1,
cyclic 30,50 guanosine monophosphate (cGMP), and sodium,
without changes in plasma ET-1.3
ET-1 acts in an autocrine and paracrine manner on two
subtypes of ET receptors, termed ET-A and ET-B.5,6 The ET-
A receptors are located on vascular smooth muscle cells and
binding of ET-1 to these sites results in sustained vasocon-
striction. However, ET-B receptors are also present on
endothelial cells where their activation leads to production
of nitric oxide and vasodilator prostanoids, and subsequent
vasodilation.7 In a previous study, we demonstrated that BNP
acts partly via the production of nitric oxide.8 Thus, it may be
that the close relationship between BNP and ET-1 production
in the kidney means that ET-1 mediates (part of) the effects
of BNP via the ET-B receptor. If this were the case, this would
introduce an interesting novel interaction for therapeutic
interventions. Indeed, currently a number of drugs are under
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investigation, which either inhibit the enzyme that degrades
natriuretic peptides (neutral endopeptidase inhibitors) or
block endothelin receptors. Both types of agents are evaluated
for their potential in the treatment of cardiovascular disease.
Concurrent administration of a neutral endopeptidase
inhibitor and a selective ET-A receptor antagonist would
greatly enhance BNP’s effect on the kidney if ET-B receptors
were to mediate these effects.
The aim of the present study, therefore, was to test this
hypothesis by investigating whether renal ET-B receptors are
involved in the renal actions of BNP. To this end, we studied
the renal and cardiac effects of BNP with and without co-
infusion of the ET-B receptor antagonist BQ-788 in a group
of healthy subjects. Because the pathophysiological role of
BNP becomes particularly evident in older patients, we
selected for this study only individuals above the age of 45
years.
RESULTS
Baseline clinical characteristics of the study participants are
summarized in Table 1.
Renal effects
At baseline, UNaV and urinary volume were comparable for
all visits (Table 2). BNP with or without co-infusion of BQ-
788 induced a significant natriuresis (Figure 1). Urinary
sodium excretion in the 1-h urine collection remained
unchanged during the placebo and the placebo/BQ-788
experiments (Figure 1). The urinary volume of the 1-h urine
collection significantly rose to 610 (335–733) ml after BNP
infusion, and to 605 (272–743) ml during the BNP/BQ-788
infusions, which differed from placebo experiments
(P¼ 0.015 and P¼ 0.037, respectively). During the other
infusions, urinary volume did not change, in spite of the
water repletion during the renal clearance study protocol.
Table 1 | Characteristics of the participants (mean7s.d.)
Characteristic Value
No. (male/female) 4/6
Age (year) 5476
BMI (kg/m2) 23.973.9
SBP (mmHg) 123711
DBP (mmHg) 78710
HR (beats/min) 6578
Urinary sodium excretion (mmol/24 h) 172749
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure
(blood pressure is the mean of three measurements by sphygmomanometer in
sitting position); HR, heart rate.
Table 2 | Baseline data of all variables (supine) before infusion of placebo, placebo combined with BQ-788, BNP, or BNP
combined with BQ-788
Variable Placebo Placebo/BQ-788 BNP BNP/BQ-788
Plasma cGMP (pmol/ml) 5.1 (3.9–6.8) 5.7 (5.0–8.6) 6.2 (4.3–7.4) 5.4 (4.3–6.8)
Plasma ET-1 (pg/ml) 2.65 (2.49–3.09) 2.69 (2.31–3.12) 2.16 (1.05–2.94) 2.84 (2.07–3.18)
MAP (mmHg) 96 (81–104) 90 (81–95) 93 (82–102) 91 (81–98)
HR (beats/min) 56 (52–59) 60 (53–61) 58 (49–59) 54 (51–69)
SV (ml) 85 (66–93) 83 (66–85) 79 (50–86) 81 (68–99)
CO (l) 4.3 (3.3–6.1) 4.3 (3.5–5.4) 4.2 (2.7–5.6) 4.3 (3.7–5.3)
TPR (dyn s/cm5) 1778 (1302–2594) 1699 (1353–2082) 1981 (1420–2908) 1648 (1217–2187)
ERPF (ml/(min 1.73 m2)) 443 (378–562) 442 (413–512) 443 (414–524) 469 (407–526)
ERBF (ml/(min 1.73 m2)) 777 (610–1038) 797 (667–918) 780 (701–869) 803 (667–914)
GFR (ml/(min 1.73 m2)) 108 (97–120) 98 (85–106) 108 (97–120) 104 (89–116)
FF (%) 24 (21–25) 22 (20–24) 22 (22–25) 21 (20–24)
RVR (dyn s/cm5) 10658 (5814–12079) 8693 (6337–11 378) 8809 (7147–12 011) 9143 (6391–11 675)
RF (%) 21 (15–33) 21 (17–25) 23 (17–31) 21 (16–24)
UNaV (mmol/h) 10.9 (8.0–16.4) 10.9 (7.9–18.2) 9.3 (6.4–20.3) 16.5 (6.3–20.2)
V (ml/h) 290 (81–401) 375 (171–461) 243 (68–481) 405 (234–449)
FTRNa (%) 99.0 (98.4–99.1) 98.8 (98.3–99.0) 98.9 (97.7–99.3) 98.5 (97.9–99.2)
Data are expressed as medians and interquartile range.
BNP, brain natriuretic peptide; CO, cardiac output; cGMP, cyclic 30 ,50 guanosine monophosphate; ERBF, effective renal blood flow; ERPF, effective renal plasma flow; ET-1,
endothelin-1; FF, filtration fraction; FTR, fractional tubular reabsorption; GFR, glomerular filtration rate; HR, heart rate; MAP, mean arterial blood pressure; RVR, renal vascular
resistance; SV, stroke volume; TPR, total peripheral resistance.
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Figure 1 | Renal responses of sodium excretion (Naþ , a), urinary
volume (b), glomerular filtration rate (GFR, c), and effective renal
plasma flow (ERPF, d) to intravenous infusion of placebo or BNP
infusion with or without co-infusion of BQ-788. Data are
presented as median and interquartile ranges. *Po0.05 versus
baseline. #Po0.05 between interventions.
Kidney International (2006) 69, 864–868 865
K van der Zander et al.: ETB antagonism and BNP in human kidney o r i g i n a l a r t i c l e
FLNa increased significantly from 879 (786–1111) mmol/h
to 953 (823–1224) mmol/h during BNP (P¼ 0.007), and
tended to increase from 918 (737–1105) mmol/h to 973
(748–1124) mmol/h during co-infusion of BNP and BQ-788
(P¼ 0.09), while placebo with (from median 918 to 972) or
without BQ-788 (from 913 to 899) infusion did not influence
FLNa. Furthermore, BNP decreased FTRNa from 98.9%
(97.7–99.3) to 97.3% (96.0–98.4) (P¼ 0.05), and combined
with BQ-788 from 98.5% (97.9–99.2) to 96.6% (96.1–97.6)
(P¼ 0.005), which differed from placebo infusion (P¼ 0.02
and P¼ 0.007, respectively). No difference in FTRNa was
observed between the combination of placebo/BQ-788 (from
median 98.8 to 98.8) and infusion of placebo alone (from
99.0 to 98.8).
Baseline renal hemodynamic variables did not differ
between visits (Table 2). GFR increased significantly (median:
þ 6%) during infusion of BNP alone (Figure 1); however,
during infusion of BNP combined with BQ-788, the change
in GFR (medianþ 6%) was not significant (P¼ 0.09).
During any of the other infusions, GFR remained unchanged.
None of the infusions induced a significant change in
effective renal plasma flow (ERPF) as compared to pre-
infusion values (Figure 1). Although at baseline ERPF did not
differ between visits, ERPF was somewhat lower following
BNP and/or BQ-788 infusion as compared to placebo
(Figure 1). This is probably related to a tendency for ERPF
to increase during placebo, and a tendency to decrease during
BNP and/or BQ-788. No differences or changes in RVR and
RF were observed between visits (data not shown).
Systemic hemodynamic effects
At baseline, no differences in mean arterial blood pressure
(MAP), heart rate (HR), stroke volume (SV), cardiac output
(CO), and total peripheral resistance (TPR) were observed
between the experiments (Table 2). MAP was not signifi-
cantly altered by any infusion (Figure 2). HR showed a small
increase during both BNP and BNP/BQ-788 infusions
(Figure 2), however, this was not different from placebo
infusion. No further differences in MAP or HR were observed
during interventions. CO showed a tendency to decrease by
14% (0–17) (P¼ 0.05) during infusion of the combination
BNP/BQ-788, but not during any of the other infusions.
There were no differences in CO or SV between visits. Finally,
during infusion of BQ-788, TPR tended to increase by 14%
(1 to 47) (P¼ 0.066), and TPR tended to increase by 13%
(3–31) (P¼ 0.05) during infusion of BNP/BQ-788.
Plasma and urinary levels of cGMP and ET-1
At baseline, cGMP plasma levels did not differ between visits
(P¼ 0.84; Table 2). Both infusion of BNP and the combina-
tion of BNP and BQ-788 significantly increased the cGMP
plasma level to 14.6 (12.6–18.9) pmol/ml and 18.7
(14.7–23.4) pmol/ml, respectively (Po0.01), while placebo
infusion with and without BQ-788 had no significant effect
on cGMP plasma levels. The percent rise in plasma cGMP
was significantly greater with infusion of BNP with or
without co-infusion of BQ-788 (119 %(84–356) and 192
%(152–415), respectively) as compared to placebo with (3
%(25 to 48)) or without (10 %(36 to 40)) co-infusion of
BQ-788 (Po0.01). Changes in urinary excretion of cGMP
followed the pattern of plasma levels (data not shown).
Baseline plasma ET-1 levels did not differ between visits
(P¼ 0.68; Table 2). During placebo infusion, plasma ET-1
levels increased to 3.4 (2.6–3.8) pg/ml (P¼ 0.046), and
increased borderline significantly during BNP infusion to
2.8 (2.7–3.6) pg/ml (P¼ 0.066). Infusion of BQ-788 com-
bined with either placebo or BNP had no significant effect on
ET-1 plasma levels. Whereas no effects, whatsoever, were seen
with respect to urinary ET-1 excretion (data not shown).
DISCUSSION
The present study was designed to test the hypothesis that the
renal effects of BNP (enhanced natriuresis and diuresis) are
mediated, at least in part, by ET-B receptors. Our data,
however, provide no evidence for such an effect.
Experiments in anaesthetized rats have shown that low
doses of intravenous ET-1 cause natriuresis by reducing
sodium transport in the proximal and distal nephron
segments. Higher doses result in sodium retention due to
(pre)glomerular vasoconstriction.9 Data obtained with ET-A-
and ET-B-specific antagonists in anaesthetized dogs indicate
that the ET-A receptor predominantly accounts for renal
vasoconstriction, while the ET-B receptor is largely respon-
sible for vasodilation, diuresis, and natriuresis.10 Studies with
selective ET-A and/or ET-B blockade in man support these
data with respect to renal vasoregulation, but not with respect
to diuresis and natriuresis.11 However, some studies reported
significant reduction in endothelin-induced decrease in
natriuresis by ET-A receptor blockers, which may have been
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Figure 2 | Supine mean arterial blood pressure (MAP, a) and heart
rate (HR, b) at baseline and following 1 h infusion of placebo or
BNP with or without co-infusion of BQ-788 for 15 min. Data are
presented as median and interquartile ranges. *Po0.05 versus
baseline.
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related to higher dosages of ET-A blockers.12,13 Our present
data, however, do not support the concept of a close
relationship between BNP and the production of ET-1 in the
kidney, which then would mediate (part of) the effects of
BNP via the ET-B receptor. First, the effects of low-dose BNP
infusion on natriuresis, diuresis, and tubular reabsorption of
sodium were not modified by ET-B receptor blockade.
Second, the fact that BNP induced a small rise in GFR, when
given alone, but not during concomitant ET-B receptor
blockade, may be the result of redirecting ET-1 from ET-B to
the ET-A receptors.10 Third, BNP infusion did not change
urinary ET-1 excretion.
Previous investigations have demonstrated that BNP is
able to induce a dose-dependent vasodilation through
activation of the natriuretic peptide receptor A (NPR-A),
with an associated increase in cGMP, as well as by production
of nitric oxide.8,14 In line with our previous work, the present
data confirmed that BNP infusion enhanced the release of
plasma and urinary cGMP, urinary sodium excretion, and
urine volume along with an increase in GFR, and filtered load
of sodium. Furthermore, BNP infusion did not change syst-
emic hemodynamics. Therefore, it is fair to conclude that the
dose of BNP, which we used, was sufficient to activate its
receptors and enhance the release of its second messenger cGMP,
yet low enough to keep systemic hemodynamics unaffected.
BNP could increase GFR in two possible ways, namely by a
change in balance of afferent and efferent tone, and/or by
changing filtration surface area. The first possibility, pre-
glomerular vasodilation combined with post-glomerular
vasoconstriction would indeed lead to increased GFR with
unchanged ERPF. Such effects have been demonstrated for
ANP,15 which render a similar mechanism for BNP likely. On
the other hand, ANP has been shown to increase cGMP levels
in mesangial cells, leading to relaxation of these cells and
subsequent enlargement of filtration surface area.16,17 There-
fore, we consider both mechanisms of the BNP-induced rise
in GFR possible.
None of the effects of BNP were modified by concurrent
administration of the ET-B receptor antagonist. Nevertheless,
an obvious limitation in this study is that we could not assess
the degree of ET-B receptor blockade. In our hands, the BQ-
788 assay is not sufficiently sensitive.11 Alternatively, infusion
of ET-1, to demonstrate a shift in the dose–response curve,
would not only stimulate ET-B but also unoccupied ET-A
receptors, making unambiguous conclusions impossible.
However, the fact that ET-B receptor blockade tended to
increase TPR suggests that we did achieve adequate
blockade.10 The dose of BQ-788 used in the present study
(50 nmol/min for 15 min; total dose 0.75 mmol) was based on
those used in previous work.11,18 These previous studies
showed that a lower dose of BQ-788 (30 nmol/min) given for
15 min causes physiologically significant systemic ET-B
receptor blockade in healthy subjects, based on an increase
in systemic vascular resistance and a reduction in heart rate,
and that a somewhat higher total dose (4.5 mmol) had clear
effects on renal function. Although we recognise this as a
limitation, it is indeed possible that a higher dose of BQ-788,
given over the hour of study, might have produced an
inhibition of the response to BNP, this is, however, unlikely
based on our previous work. Also, we are concerned that higher
doses19 might not have retained ET-B receptor selectivity
(selectivity B1000-fold ET-B/ET-A), and by also blocking the
ET-A receptor might have produced misleading results.
Irrespective of the mechanisms, the intrarenal natriuretic
and hemodynamic effects of BNP were not affected by the
antinatriuretic action of BQ-788. It is possible that the renal
effect of BNP overruled ET-B receptor antagonism, but this is
unlikely as we used a low dose of BNP. Therefore, we
conclude that ET-B receptors are not involved in the BNP-
induced stimulation of natriuresis.
MATERIALS AND METHODS
Subjects
Experiments were performed in 10 healthy volunteers, recruited by
advertisement in local papers. Inclusion criteria were: age between
45 and 70 years and normal blood pressure (o140/90 mmHg, mean
of three office measurements). Exclusion criteria were: diabetes, a
history of or signs of cardiovascular disease, any major systemic
malignancy, and the use of any medication in the 2 weeks prior to
selection. During the week prior to the measurements, all subjects
adhered to a 175 mmol Naþ -containing diet so as to minimize
variations in results due to differences in salt intake. Compliance
with the diet was checked by measuring sodium and creatinine
output in 24-h urine collections obtained during the last 24 h before
the experimental day. None of the subjects used any medication
(including non-steroidal anti-inflammatory drugs) during the 2
weeks prior to the measurements. In addition, they had to refrain
from smoking and drinking caffeine or alcohol containing beverages
for at least 12 h before the experiments, which started at 0830 hours
after an overnight fast. The Medical Ethics Committee of the
Maastricht University Hospital approved the study, and all
participants gave written informed consent. The investigations
conformed to the principles outlined in the Declaration of
Helsinki.20
Experimental design
The study was designed as a four way crossover trial. All volunteers
were studied on four separate occasions (at least 2 days apart),
during which they received in random order (double blind) an i.v.
infusion of either vehicle (glucose 5%), a combination of placebo
with BNP, placebo combined with BQ-788, or BNP combined with
BQ-788. Experiments were performed in a quiet, temperature-
controlled room. Precautions were taken to minimize external
disturbances. Subjects remained supine throughout the experiments.
A 20-gauge catheter was inserted into the antecubital vein of both
arms. One was connected to a three-way tap for infusion of placebo,
BNP, BQ-788 (both from Clinalfa; Ethifarma Nederland BV, The
Netherlands) and para-amino hippurate (PAH)/inulin (for measur-
ing renal hemodynamics), while the other was used for blood
sampling. To ensure adequate diuresis, subjects consumed 200 ml of
water every hour until the last blood samples had been drawn. At
t¼ 0 min, the PAH/inulin infusion was started and an echocardio-
gram was taken. At t¼ 120 min, the intravenous infusion of either
placebo (glucose 5%), a combination of placebo with BNP (4 pmol/
kg/min), placebo combined with BQ-788 (50 nmol/min), or BNP
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combined with BQ-788 was started. Based on our previous studies,
these relatively low doses of BNP and BQ-788 were suspected to
influence renal, but not systemic hemodynamics.18,21 Infusion of
BQ-788 stopped at t¼ 135 min. At t¼ 180 min (i.e. after 1 h of
placebo or BNP infusion), a second echocardiogram was performed.
Blood pressure and HR were measured at 10-min intervals during
the infusion in supine position, and before and after the
measurements in sitting position. Blood samples were drawn at
t¼ 0, t¼ 120, and t¼ 180 min for PAH and inulin, and at t¼ 120
and t¼ 180 min for determination of hematocrit, cGMP, and ET-1.
Urine samples for measurement of sodium, cGMP, and ET-1 were
collected at t¼ 60, t¼ 120, and t¼ 180 min (immediately after
blood sampling).
Measurements
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and
HR were measured by an automatic oscillometric device (Dinamap
Vital Signs Monitor 1846, Critikon, Tampa, FL, USA). CO was
measured by echocardiography and total peripheral resistance
(TPR) was calculated as (MAP/CO) * 80 and expressed in dyn s/
cm5.
Renal hemodynamics, that is, ERPF and GFR, were measured as
the clearance of PAH (MSD, West Point, PA, USA) and inulin
(Inutest, Laevosan Gesellschaft, Linz, Austria), respectively, during
continuous infusion of both substances.22 Both GFR and ERPF were
corrected for body surface area and expressed as ml/(min 1.73 m2).
Effective renal blood flow (ERBF) was calculated by the following
formula: ERBF¼ ERPF/(1hematocrit). Renal vascular resistance
(RVR) was calculated as (MAP/ERBF) * 80 000 and expressed in
dyn s/cm5. Renal fraction (RF) was calculated as (ERBF/CO) *
100%. Filtered load (FL) is calculated as GFR * 60 * [Naþ ]plasma and
expressed in mmol/h. Fractional tubular reabsorption (FTR) is
calculated as ((FLUNaV)/FL) * 100%, where UNaV stands for
the amount of Naþ excreted in the urine, and expressed also in
mmol/h.
Assay methods
PAH and inulin levels were measured by means of a spectro-
photometer. cGMP levels were measured with a competitive
protein-binding RIA (IBL Hamburg RE 29071, IBL, Hamburg,
Germany). ET-1 was determined by standard RIA (Peninsula
Laboratories Europe, Bachem, Merseyside, UK). In our hands, the
intra- and interassay variability of all assays was o10%.
Statistics
As their distribution was not normal, data are presented as medians
with interquartile ranges, unless stated otherwise. The primary
outcome variable in this study was the difference in natriuretic
response during combined BNP/BQ-788 infusion relative to that
during BNP alone. Secondary analyses comprised the effects of the
interventions on renal hemodynamics. Friedman’s test (non-
parametric two-way ANOVA) was used for analysis of multiple
related samples (between visits), and Wilcoxon paired sign test for
paired analysis (both within one visit and between visits). P-values
below 0.05 denote statistical significance. In case a Friedman’s test
demonstrated statistical significance, post hoc analyses was per-
formed by a Wilcoxon paired sign test. Based on previous
experiments, we calculated that this study is able to demonstrate a
10% difference in any of the test variables with a power of 80% in 10
experimental subjects.
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